Losartan Cost in District of Columbia 2026

What Does Losartan Actually Cost in DC Right Now?

Generic losartan tablets cost approximately $10 per month at DC retail pharmacies when paid out of pocket in 2026, and discount cards from GoodRx or RxSaver routinely bring that figure to $4, $9 depending on the pharmacy and the strength prescribed. Branded Cozaar, still sold by Merck, carries a list price near $80 per month, but branded prescribing is rare now that bioequivalent generics are widely stocked.

Losartan belongs to the angiotensin II receptor blocker (ARB) drug class. The FDA approved the original branded product in 1995 for hypertension, later expanding labeling to include reduction of stroke risk in patients with hypertension and left ventricular hypertrophy (LVH), and to slow the progression of diabetic nephropathy in patients with type 2 diabetes [1]. Generic manufacturers entered the market after 2010, and by 2026 the wholesale acquisition cost for a 30-tablet supply of 50 mg generic losartan sits well below $15 at most DC wholesalers.

Price varies by pharmacy chain. CVS, Walgreens, Giant Food, and Walmart locations across the District stock generic losartan in all three strengths (25 mg, 50 mg, 100 mg). Walmart's $4 generic program covers losartan 50 mg for a 30-day supply at participating DC stores, making it one of the lowest-cost options without any coupon. Costco Pharmacy on Gallows Road (just outside DC) frequently shows prices around $5, $7 for a 90-day supply when checked through GoodRx's tool.

The key takeaway: almost no DC patient should pay the $80 branded list price. A quick comparison on GoodRx.com, NeedyMeds.org, or the pharmacy's own app before filling the prescription takes under two minutes and can cut the bill by 90 percent [2].

How DC Medicaid Covers Losartan

DC Medicaid (administered under the DC Department of Health Care Finance) covers generic losartan on its preferred drug list, but the coverage comes with a prior authorization (PA) requirement in most cases [3]. That PA requirement is not unusual for ARBs; DC Medicaid typically prefers that prescribers document a clinical reason for bypassing lower-cost ACE inhibitors like lisinopril before authorizing an ARB.

For patients who cannot tolerate ACE inhibitors due to cough or angioedema, the PA approval rate is high. A prescriber documents the intolerance, submits the PA form to DC's Medicaid portal, and the authorization is usually returned within 72 hours for non-urgent cases. Emergent situations may qualify for a 72-hour supply dispensed before PA completion.

DC Medicaid enrollees who receive losartan through managed care organizations (MCOs) such as AmeriHealth Caritas DC, MedStar Family Choice DC, or Trusted Health Plan DC should verify the specific formulary tier with their plan, since each MCO negotiates its own drug list within DC Medicaid rules. The DC Department of Health Care Finance publishes updated formulary supplements quarterly at dhcf.dc.gov [3].

Dual-eligible patients (Medicare Part D plus DC Medicaid) may find losartan on the formulary of their Part D plan at a $0 or Tier 1 copay. Medicare Part D low-income subsidy (LIS) beneficiaries pay no more than $4.50 per prescription for generic drugs in 2026 under federal LIS rules [4].

The Joint National Committee guidelines (JNC 8, 2014) explicitly list ARBs including losartan as first-line agents for hypertension in patients with chronic kidney disease and diabetes [5]. That guideline language supports PA approval when a DC Medicaid prescriber cites diabetic nephropathy or CKD as the indication.

Is Compounded Losartan Legal in DC?

Compounded losartan is legal in DC when prepared by a state-licensed 503A pharmacy operating under a valid prescription for an individual patient [6]. The District of Columbia Board of Pharmacy regulates 503A compounding pharmacies and requires compliance with USP standards (USP 795 for non-sterile compounding). Losartan is not on the FDA's 503B outsourcing facility bulk drug list, so commercial-scale compounding for office stock is not permitted, but patient-specific compounding by a licensed 503A pharmacy is allowed.

Why would a DC patient want compounded losartan? The most common clinical reason is a need for a strength or combination not commercially available. Pediatric patients, for example, may require an oral suspension rather than a tablet. Some compounding pharmacies also produce losartan in strengths below 25 mg for patients who need gentle titration. A second scenario involves patients enrolled in specific telehealth or cash-pay clinical programs where the compounding pharmacy's total price, including the prescribing fee, comes to $0 per month.

One caution: the FDA does not review compounded drugs for safety, efficacy, or quality the way it reviews manufactured generics [6]. Generic losartan from a licensed manufacturer has passed bioequivalence testing confirming it delivers the same blood-level exposure as branded Cozaar [1]. Compounded formulations have not undergone that testing. For patients who can take commercially available generic tablets, the generic is the better-validated option.

DC residents considering a compounded product should verify that the pharmacy holds an active DC Board of Pharmacy license, confirm USP 795 compliance, and ask whether the pharmacy participates in any accreditation program such as PCAB (Pharmacy Compounding Accreditation Board).

Clinical Evidence Behind Losartan: Why Physicians Prescribe It

Losartan's evidence base is substantial. The LIFE trial (Losartan Intervention For Endpoint reduction in hypertension), published in The Lancet in 2002 with 9,193 patients, found that losartan 50 to 100 mg/day reduced the composite endpoint of cardiovascular death, stroke, and myocardial infarction by 13 percent compared with atenolol 50 to 100 mg/day (relative risk 0.87 to 95% CI 0.77, 0.98, P<0.021) in patients with hypertension and electrocardiographic LVH [7]. Stroke reduction drove most of the benefit: losartan cut fatal and non-fatal stroke by 25 percent versus atenolol.

The RENAAL trial (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan), published in the New England Journal of Medicine in 2001 with 1,513 patients who had type 2 diabetes and nephropathy, found that losartan 50 to 100 mg daily reduced the risk of the composite of doubling of serum creatinine, end-stage renal disease, or death by 16 percent versus placebo (P<0.02) [8]. It also reduced the rate of first hospitalization for heart failure by 32 percent.

These two trials are the primary reason DC Medicaid PA reviewers generally approve losartan when the prescriber documents LVH or diabetic nephropathy as the indication, directly matching the trial populations [5, 7, 8].

The 2023 American College of Cardiology/American Heart Association hypertension guidelines recommend ARBs as first-line therapy for patients with hypertension complicated by CKD with proteinuria, citing a Grade I, Level A recommendation [9]. For DC prescribers writing PA letters, quoting that guideline designation alongside the RENAAL data is typically sufficient for approval.

Losartan Safety Profile and Monitoring in DC Clinical Practice

Losartan is generally well tolerated. The most clinically significant risks are hyperkalemia and acute kidney injury, particularly in patients already taking potassium-sparing diuretics or with reduced baseline GFR [1]. The FDA label recommends baseline renal function and electrolyte panels before initiation, with follow-up labs at 2 to 4 weeks after starting or after any dose increase [1].

Unlike ACE inhibitors, losartan does not inhibit the enzyme that degrades bradykinin, which means the dry cough that prompts many patients to switch from lisinopril to losartan occurs at a rate essentially equal to placebo. A 2009 meta-analysis in the Annals of Internal Medicine covering 72 trials found ARB-associated cough rates indistinguishable from placebo, compared with an ACE inhibitor cough incidence of roughly 10 percent [10].

Angioedema can occur with losartan but is rare and less common than with ACE inhibitors [1]. Patients with a prior history of ACE inhibitor angioedema should still be counseled that cross-reaction with ARBs is possible, though the absolute risk is low.

Losartan is teratogenic in the second and third trimesters. The FDA label carries a black-box warning against use in pregnancy, requiring immediate discontinuation if pregnancy is detected [1]. DC providers prescribing through telehealth platforms must obtain a medication history that screens for pregnancy or pregnancy intent before initiating.

Blood pressure targets align with the 2023 ACC/AHA guidelines: a goal of <130/80 mmHg for most adults, and the same target for patients with CKD or diabetes [9]. Losartan's 24-hour duration of action after once-daily dosing supports consistent blood pressure control through the morning surge hours, a pharmacokinetic feature confirmed in multiple ambulatory blood pressure monitoring studies [11].

Getting a Losartan Prescription via Telehealth in DC

DC residents can legally receive a losartan prescription through a telehealth visit. The District of Columbia allows prescribers licensed in DC to conduct synchronous (video or audio) or asynchronous telehealth visits and issue prescriptions for non-controlled medications including losartan [12]. The Ryan Haight Online Pharmacy Consumer Protection Act, which restricts controlled-substance prescribing, does not apply to losartan.

A typical telehealth workflow for losartan in DC runs as follows. The patient completes an intake form with blood pressure history, current medications, and any prior lab work. A DC-licensed physician or nurse practitioner reviews the intake and conducts a video visit, usually 10 to 15 minutes. If appropriate, a prescription is sent electronically to the patient's preferred DC pharmacy or a mail-order pharmacy. Some platforms send the prescription directly to a 503A compounding pharmacy if that fits the clinical and financial situation.

Most telehealth platforms serving DC charge $0, $75 for an initial visit for hypertension, with follow-up visits priced lower. When the total annual cost of telehealth visits plus generic losartan is compared with an in-person visit plus a retail prescription, the difference is often negligible. The primary financial advantage of telehealth is convenience, not drug cost, since generic losartan is already inexpensive at DC retail pharmacies.

DC's telehealth parity law (DC Code § 31-3861 et seq.) requires that commercial insurers cover telehealth visits at the same reimbursement rate as equivalent in-person visits, which means patients with DC-regulated commercial insurance should not pay more for a telehealth prescribing visit than for an office visit [12].

Which Insurance Plans Cover Losartan in DC?

Virtually every commercial insurance plan operating in DC covers generic losartan, typically at Tier 1 or Tier 2. Tier 1 copays in DC plans sold on the ACA marketplace typically range from $0 to $10 per 30-day fill. Tier 2 copays run $15, $40. Branded Cozaar, when it appears on formularies at all, usually lands at Tier 3 or Tier 4 with copays of $50, $100 or higher.

Major carriers operating in DC include CareFirst BlueCross BlueShield, Kaiser Permanente Mid-Atlantic, and Aetna (via CVS Health). Each publishes a searchable formulary on its website. The DC Health Link (DC's ACA marketplace) allows side-by-side formulary comparison before plan enrollment each November.

Employer-sponsored plans regulated under ERISA are not subject to DC state insurance law but typically follow similar formulary conventions. HR or benefits departments can confirm the drug tier for losartan on request, and most large employers use a pharmacy benefit manager (PBM) that places generic ARBs at Tier 1.

Medicare Part D plans available to DC residents list losartan on nearly every formulary. The Medicare Plan Finder at medicare.gov allows patients to enter their exact medication list and DC zip code to see plan-specific copays side by side [4].

DC Losartan Discount Programs and Savings Options

Several cost-reduction pathways are available to DC residents regardless of insurance status.

GoodRx and similar apps. Free coupons available at GoodRx.com, RxSaver, or Blink Health routinely price generic losartan at $4, $9 for a 30-day supply at DC pharmacies. These coupons cannot be combined with insurance but are useful for uninsured patients or those whose Tier 1 copay exceeds the coupon price [2].

Merck Patient Assistance Program. Merck offers a patient assistance program for branded Cozaar through the Merck Patient Assistance Program (Merck Helps), intended for uninsured or underinsured patients who meet income criteria. Given the $10 cash price of the generic, this program is rarely the most practical path, but it exists for patients who have a documented clinical need for the branded formulation [13].

DC Pharmaceutical Assistance for the Aged and Disabled (PAAD). DC's PAAD-equivalent programs and the DC Healthy Families program may cover losartan for qualifying low-income residents who do not yet meet Medicaid eligibility. Income thresholds and enrollment instructions are available at dhcf.dc.gov [3].

NeedyMeds.org. This nonprofit database aggregates patient assistance programs, disease-specific funds, and pharmacy discount programs. Searching for losartan at NeedyMeds returns both manufacturer assistance and independent foundation grants that can offset copays for insured patients with cost-sharing burdens.

340B pharmacies. Several DC health centers, including federally qualified health centers (FQHCs) serving uninsured and underinsured patients, participate in the 340B drug pricing program. Under 340B, the pharmacy's acquisition cost for generic losartan drops to cents per tablet, and many FQHCs pass that savings to patients as a $0 or $1 copay. Unity Health Care, Community of Hope, and other DC FQHCs may offer this benefit.

Practical Prescribing Doses and Titration for DC Providers

Losartan is initiated at 50 mg once daily for most adults with hypertension. Patients with volume depletion (common in patients on diuretics) or hepatic impairment may start at 25 mg once daily to minimize hypotensive risk [1]. The maximum approved dose is 100 mg per day.

For diabetic nephropathy, the RENAAL trial used 50 mg/day titrated to 100 mg/day based on blood pressure response, with 72 percent of patients reaching the 100 mg dose by trial end [8]. DC Medicaid PA forms requesting losartan for nephropathy should document the target dose trajectory alongside baseline urine albumin-to-creatinine ratio (UACR) and GFR.

Dose adjustments for renal impairment are generally not required based on pharmacokinetic data in the FDA label, though clinical judgment favors caution (and more frequent lab monitoring) when GFR drops below 30 mL/min/1.73m² [1]. Losartan and its active metabolite EXP3174 are hepatically metabolized by CYP2C9 and CYP3A4; patients who are CYP2C9 poor metabolizers may have higher drug exposure and slightly greater blood pressure response at standard doses [11].

Drug interactions of note in DC clinical practice: concomitant use of NSAIDs (common in older DC patients managing arthritis) can blunt losartan's antihypertensive effect and increase renal risk. Dual RAAS blockade, combining losartan with an ACE inhibitor or with aliskiren, is not recommended based on the ONTARGET trial finding of increased renal adverse events without additional cardiovascular benefit [14].

DC-Specific Access Considerations

DC has no state income tax exemption specifically for prescription drugs that changes the out-of-pocket cost at the pharmacy counter. However, the DC Earned Income Tax Credit and certain low-income programs indirectly affect how much disposable income patients have available for medications.

DC residents near the Maryland or Virginia border may find lower prices at pharmacies just across the line in some cases, though the difference for a drug already priced at $4, $10 is minor. What matters more is which discount card or program is applied at checkout.

For patients without a primary care physician in DC, walk-in clinics at CVS MinuteClinic, Walgreens Health (where operating), and MedStar Prompt Care locations can evaluate and prescribe for hypertension at an initial visit. Many of these sites now offer a transition to telehealth follow-up, keeping the medication cost low and reducing transportation barriers.

The DC Department of Health's Community Health Needs Assessments have repeatedly documented hypertension prevalence above 40 percent in Wards 7 and 8, the city's lowest-income areas [15]. For those communities, combining a free FQHC visit with a 340B-priced generic losartan prescription, or a GoodRx coupon at a nearby pharmacy, is the most cost-effective path to blood pressure control.